OSR Unit Vaximm Reports Positive Results for Brain Cancer Therapy; Shares Jump

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

OSR Unit Vaximm Reports Positive Results for Brain Cancer Therapy; Shares Jump

, MT Newswires - 8:13 AM ET 3/26/2025 default

08:13 AM EDT, 03/26/2025 (MT Newswires) -- OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.

The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.

The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.

The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.

OSR shares climbed by nearly 130% in premarket trading.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.